Recent Security Class Actions

The Complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about Biogen’s business, operations, and prospects. Further, the Complaint alleges that Defendants engaged in irregular and potentially illegal meetings with the FDA in an attempt to find a path forward for approval of Adulhelm.